Cingulate Inc.
CING- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001862150
No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $9.88M in total; no superinvestor holds it.
Other share classesCINGW
Q3 2022 vs. Q2 2022
How the institutions holding Cingulate Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 8 | 8 | 0 |
| Shares | 661.5K | 265.1K | −396.4K (−59.9%) |
| Value | $963.9K | $283.0K | −$680.9K (−70.6%) |
New holders (3)
Institutions that held Cingulate Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 15,077 | $16.0K | 0.00% |
| Ergoteles LLC | 11,399 | $12.0K | 0.00% |
| Morgan Stanley | 37 | $0 | 0.00% |
Sold out (3)
Institutions that held Cingulate Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Renaissance Technologies LLC | 44,600 | $65.0K |
| Creative Planning | 23,510 | $34.0K |
| StoneX Group Inc. | 15,000 | $21.9K |